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Public Health Regulation: 
Convergence, Divergence, and Regulatory Tension – an Asian Perspective 
Locknie Hsu∗ 
 
 
 
1. Introduction: the Intersection of Treaties and Public Health 
International economic agreements such as bilateral investment treaties (BITs) and free trade 
agreements (FTAs) deal primarily with economic and attendant legal issues, and disputes arising 
from their investment provisions usually relate to State regulatory measures which cause economic 
displacement and loss to foreign investors. Many such treaties in the past did not place any emphasis 
on the importance of treaty exceptions such as those which allow for health regulation measures. In 
fact, many older BITs do not mention health at all. Health exceptions have recently gained more 
prominence in economic treaties, some of them incorporating the familiar language of Article XX(b) 
of the World Trade Organization’s GATT 1994, or some variant of it.1 In some agreements, health-
∗ Associate Professor, School of Law, Singapore Management University, LL.B.(NUS), LL.M. (Harvard), 
Advocate & Solicitor (Singapore); email: lockniehsu@smu.edu.sg. 
1  Art. XX(b) reads: “Subject to the requirement that such measures are not applied in a manner which would 
constitute a means of arbitrary or unjustifiable discrimination between countries where the same conditions 
prevail, or a disguised restriction on international trade, nothing in this Agreement shall be construed to 
prevent the adoption or enforcement by any contracting party of measures: 
… 
(b) necessary to protect human, animal or plant life or health; …”. 
For examples of recent treaties with similar exception provisions, see for example Art. 17 of the ASEAN 
Comprehensive Investment Agreement (ACIA), signed 26 February 2009, in force from 29 March 2012. 
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related exemption provisions have also begun to appear in the context of explaining the scope of 
indirect expropriation provisions.2 
Such textual shifts have not occurred on their own, but rather, have taken place against a broader 
background of legal developments. These include the rapid growth of investor-State disputes, some 
of which have begun to involve investor challenges to public-health protection State measures. This 
can be seen in the area of tobacco control, where a number of legal actions are ongoing in various 
fora against States for their laws on tobacco control. Some of these involve business-party claims 
against the State based on, inter alia, arguments of treaty violations in relation to the claimant’s 
intellectual property rights.3 States, on the other hand, argue that they have an obligation (and right) 
to regulate in order to protect public health. This perfectly exemplifies the emerging type of trade-
investment law-public health regulation interface – and resulting regulatory tension - faced by many 
States today. 
Apart from such instances of actual disputes, another interface between trade, investment and health 
regulation which has caused regulatory tension can be seen in the area of pharmaceutical regulation. 
Two key forces have been at work here. 
First, there have been heated debates at the multilateral level – such as in international fora like the 
WTO and the WHO – over the balance needed between the protection of intellectual property 
rights (specifically, patents and confidential data) for pharmaceutical inventions to promote 
innovation on one hand, and public access to affordable medicines, particularly in poorer countries, 
on the other. Specifically, the effect of obligations in the TRIPS Agreement, flexibilities permitted to 
members under the Agreement and their implications for members’ access to affordable medicines 
have come under intense scrutiny and are of deep concern to many members, especially since a 
majority of WTO members are developing and least developed countries. In 2013, the WHO, WTO 
and WIPO cooperated in a landmark trilateral study on the interface of intellectual property rights, 
public health and trade, reflecting further the growing interfaces of these areas, divergent views and 
policies on them, and resulting tensions.4 
Access to medicines in emergencies or situations of extreme urgency in member countries has been 
part of this debate at the WTO, resulting in the 2001 Doha Declaration on TRIPS and Public Health, 
and changes to the TRIPS regime on compulsory licensing.5 
2  See, for example, Annex B of the US Model BIT 2012 (available at: 
www.ustr.gov/sites/.../BIT%20text%20for%20ACIEP%20Meeting.pdf, and Annex 3 of the Comprehensive 
Economic Cooperation Agreement between the Republic of India and the Republic of Singapore (CECA), signed 29 June 2005, 
in force from 1 August 2005. 
3  See, for example, the arbitral action brought by Philip Morris Asia against Australia for its plain-packaging law: 
http://www.ag.gov.au/internationalrelations/internationallaw/pages/tobaccoplainpackaging.aspx (accessed 16 
June 2014). 
4  Promoting Access to Medical Technologies and Innovation: Intersections between public health, intellectual property and trade 
(2013); the study is available at: http://www.wto.org/english/tratop_e/trips_e/who_wipo_wto_e.htm. 
5  Members have agreed to a waiver of Article 31(f) of the TRIPS Agreement in paragraph 6 of the Declaration 
(the “Paragraph 6 Waiver”), pending TRIPS amendment; see WTO website at: 
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 Secondly, a number of TRIPS flexibilities have been reduced for certain States which have entered 
into FTAs containing standards stricter than those in TRIPS. For example, some FTAs have 
resulted in limiting the flexibility as to what may be excluded from patentability, while others have 
imposed stricter requirements for the protection of confidential data (such as clinical tests data) than 
what TRIPS requires. Such provisions, called “TRIPS-plus” provisions, in effect provide rights 
holders with a degree of protection exceeding that under TRIPS. Moreover, because such FTAs 
typically permit investor-State arbitration, a rights holder gains a direct avenue of complaint against 
the State for any claims of violation of these provisions. 
The increase in FTA commitments that have an impact both on the patenting and approval (or 
licensing) of pharmaceuticals contributes to this intersection in significant ways. Not only are 
TRIPS-plus commitments appearing, but these may vary from treaty to treaty, leading to divergent 
requirements in signatory states. The 2013 trilateral study mentioned above stated that convergence 
of international regulation on health and medical technologies “is a challenge” as countries have 
their own regulatory and administrative and technical systems. 6 However, the study added that 
“[c]onvergence of the different national systems, in conjunction with harmonization of technical 
requirements, can remove many of the transactional and human resource costs associated with 
multiple regulatory submissions in each country, including multiple testings.” 
Meanwhile, demandeur States are continuing to request stronger TRIPS-plus treaty protection in 
current negotiations, such as those in the Trans-Pacific Partnership Agreement (TPP). Four ASEAN 
states with varying levels of economic development, healthcare policies and IPR priorities are 
participants in these negotiations (Brunei Darussalam, Malaysia, Singapore and Vietnam). Among 
these, there are varying levels of emphasis on IPR protection, with Singapore being probably the 
strongest IPR proponent, as it explicitly aims to be an “IP hub” as well as a hub for development of 
biomedical products and services.7 
In a region such as Asia which comprises high-income countries and least developed countries, 
differing priority health needs and ability of citizens to pay for medicines can also give rise to 
divergent trade, IP and health laws and policies.8 
This article provides some examples of divergences on IP-health policies in members of the 
Association of Southeast Asian Nations (ASEAN) 9 and some of its regional trade partners, such as 
http://www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm (accessed 16 June 2014). The waiver is 
aimed at increasing access – via a combination of compulsory licensing and permission to export (in a 
departure from Article 31(f)) – for members which have no capacity to manufacture necessary medicines 
themselves. 
6  Note 4 above, at p 49. 
7  See Singapore IP Hub Master Plan – Developing Singapore as a Global IP Hub in Asia, IP Steering Committee, 2013: 
http://www.ipos.gov.sg/Portals/0/Press%20Release/IP%20HUB%20MASTER%20PLAN%20REPORT%2
02%20APR%202013.pdf (accessed 16 June 2014). See also the Singapore Economic Review Committee Report 
(2003) and sub-committee reports: 
http://www.mti.gov.sg/AboutMTI/Pages/Economic%20Review%20Committee.aspx (accessed 16 June 2014). 
8  See for example the discussions in Srividhya Ragavan, Patent and Trade Disparities in Developing Countries, (2012) 
Oxford University Press. 
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 China, India, Korea and Japan. 10  These represent some of the most active countries in FTA 
negotiations in the region over the last decade. 
 
2. TRIPS: Convergence in WTO members’ minimum requirements in intellectual 
property rights protection and enforcement 
The TRIPS Agreement provides a minimum set of standards for protection for IPRs in WTO 
members. This means that while members may exceed these minimum standards or systemic 
requirements, they are not under any compulsion to do so. This leaves them with a degree of 
flexibility in regulating intellectual property rights beyond these minimum requirements. This was 
the nature of the agreement reached by founding members of the WTO through a series of 
negotiating trade-offs in various areas of trade. 
In establishing minimum requirements, the TRIPS Agreement has been the catalyst for a certain 
degree of convergence in member States’ laws on IPRs. While TRIPS does not mandate that the 
implementing national laws should be identical, they must at the very minimum provide for certain 
features (such as availability of a system for patent and trade mark registrations) and for a minimum 
level of enforcement and institutional structures for this purpose. With the exception of least 
developed countries (LDCs) that enjoy transitional exemptions, WTO members are therefore 
expected to comply with the TRIPS framework.11 
3. TRIPS Flexibilities: Room for Divergence 
As the TRIPS Agreement provides minimum requirements for national patent systems, WTO 
members enjoy a degree of flexibility with regard to national laws on pharmaceutical patents and in 
the regulation of pharmaceutical products. Three areas of such flexibility serve as illustrations here; 
these are by no means exhaustive. 
 
First, Article 27 of TRIPS permits members – if they so choose – to exclude certain subject matter 
from being patentable. As a result, within this permissive framework, members have patentability 
provisions of varying scope in their national laws.  Articles 27.2 and 27.3 provide, respectively: 
 
9  For ASEAN countries, regional forces such as the ASEAN economic integration plan are at work as well, with 
an ASEAN Economic Community (AEC) to be set up by the end of 2015. The AEC forms part of a greater 
integration plan which includes two other Communities or “pillars”, namely, the ASEAN Political-Security 
Community (APSC) and the ASEAN Socio-Cultural Community (ASCC). The ASCC and other ASEAN 
statements have referred to the importance of ensuring affordable healthcare and medication - see for example 
the recent Bali Declaration on ASEAN Community in a Global Community of Nations (Bali Concord III), signed by 
ASEAN leaders on 17 November 2011, Part C, Socio-Cultural Cooperation, section 3, paragraph (c).  
10  The UN Statistics Division utilizes divisions in Asia according Central Asia, Eastern Asia, Southeast Asia and 
South Asia; see https://unstats.un.org/unsd/methods/m49/m49regin.htm#asia (accessed 6 March 2014).  The 
ADB utilizes a list of 48 countries as being part of Asia and the Pacific: http://www.adb.org/countries/main 
(accessed 6 March 2014).  
11  See, for example, LDCs’ TRIPS exemptions at: http://www.wto.org/english/tratop_e/trips_e/ldc_e.htm 
(accessed 16 June 2014). 
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 2. Members may exclude from patentability inventions, the prevention within their territory of 
the commercial exploitation of which is necessary to protect ordre public or morality, including 
to protect human, animal or plant life or health or to avoid serious prejudice to the 
environment, provided that such exclusion is not made merely because the exploitation is 
prohibited by their law. 
 
3. Members may also exclude from patentability: 
(a) diagnostic, therapeutic and surgical methods for the treatment of humans or animals; 
(b) plants and animals other than micro-organisms, and essentially biological processes for 
the production of plants or animals other than non-biological and microbiological processes. 
However, Members shall provide for the protection of plant varieties either by patents or by 
an effective sui generis system or by any combination thereof. … 
(Italic emphasis added to exclusionary language above; original footnote omitted.) 
 
Secondly, TRIPS permits the use of exclusive data of a party provided that certain requirements are 
met. Article 39.3 provides: 
 
Members, when requiring, as a condition of approving the marketing of pharmaceutical or of 
agricultural chemical products which utilize new chemical entities, the submission of 
undisclosed test or other data, the origination of which involves a considerable effort, shall 
protect such data against unfair commercial use. In addition, Members shall protect such 
data against disclosure, except where necessary to protect the public, or unless steps are taken to ensure 
that the data are protected against unfair commercial use. (Italic emphasis added.) 
 
The origination of the data must pass a threshold test: “origination … which involves a considerable 
effort”. Next, the protection above is directed at guarding gainst “unfair commercial use”, which is 
not defined in the TRIPS Agreement. In addition, members may depart from protection of such 
data “where necessary to protect the public”. This is a wide provision limited by showing “necessity”, 
and could arguably include protection of public health. 
Thirdly, TRIPS permits members to make use of compulsory licensing (i.e. licensing of a patented 
product without the consent of the patent owner) under certain circumstances. Article 31 allows 
members to determine what constitutes a national emergency or cases of extreme urgency, in which 
case compulsory licensing may be called into use. The Doha Declaration on the TRIPS Agreement 
and Public Health reiterated such flexibilities. 12  As a result, members’ laws may differ on the 
circumstances under which compulsory licensing may be permitted. 
In addition, Article 8 of the TRIPS Agreement provides a broad exception as follows: 
“Article 8 
12  See http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm (accessed 16 June 2014). 
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 Principles 
1. Members may, in formulating or amending their laws and regulations, adopt measures 
necessary to protect public health and nutrition, and to promote the public interest in sectors of 
vital importance to their socio-economic and technological development, provided that such 
measures are consistent with the provisions of this Agreement.  …” (Italic emphasis added.) 
Outside the WTO, several FTAs contain provisions which circumscribe such areas of flexibility 
mentioned. Such provisions, which impose stricter requirements than TRIPS, are often referred to 
as “TRIPS-plus” provisions. For example, the scope for limiting subject matter that is patentable has 
been restricted in some FTAs. As a result, such states are arguably at a relative regulatory 
disadvantage as compared with those which still enjoy the benefits of Articles 27.2 and 27.3. 
Two FTAs signed by Asian states with the United States contain examples of TRIPS-plus provisions. 
These are the US-Singapore FTA and the Korea-US FTA. Both are high-income Asian countries 
with geopolitical interests in having strengthened ties with the US. Evidently, despite the fact that 
such provisions sacrifice some of the flexibility under TRIPS, the calculation had been made that 
these are acceptable provisions.13 
 
4. TRIPS Flexibilities and Asia’s Regulatory Divergences 
 
Before discussion divergences in trade and health policies, it is noteworthy that in the use of TRIPS 
flexibilities, there is some divergence in the laws and policies of Asian countries. This is hardly 
surprising since, as mentioned, the TRIPS Agreement mandates minimum standards of IPR 
protection and enforcement, and leaves it open to member states to determine the precise content 
of their laws and regulations in areas within the flexibilities. The following are some examples of 
flexibilities used in divergent ways in Asia. 
 
a) Patentability 
 
As mentioned, Article 27 of TRIPS permits a degree of flexibility with regard to the scope of 
patentability, a basic requirement for an inventor to gain exclusive rights in the national laws of 
WTO members. Patentability is thus an important threshold matter which helps authorities 
determine whether to grant exclusive rights to a pharmaceutical innovator. Such a grant could greatly 
affect the price of the resulting pharmaceutical product, and therefore, the public’s ultimate access to 
it. 
 
In Asian patent laws, this flexibility has been exercised in a number of different ways. These include 
how the laws treat known pharmaceutical substances for which new uses have been found. As the 
13  See, for example, Chapters 3 and 12, eds. Tommy Koh and Chang Li Lin, The United States Singapore Free Trade 
Agreement – Highlights and Insights, Institute of Policy Studies and World Scientifc Publishing Co Pte Ltd, 2004. 
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 TRIPS Agreement does not specifically address such “inventions” members are free to determine 
their patentability in national systems.  
 
In India, for example, for a known drug to be patentable the Indian Patents Act requires proof of 
improvement in therapeutic efficacy; merely presenting a different form of a known drug without 
such proof of improved therapeutic efficacy is insufficient for the new product to be patentable.14 
Similarly, in the Philippines, “enhanced efficacy” is required before such products may be patented.15  
 
Under Chinese patent law, while second medical use is not specifically addressed, the relevant 
provision on patentability provides as follows: “Inventions and utility models for which patent rights 
are to be granted shall be ones which are novel, creative and of practical use.… Novelty means that 
the invention or utility model concerned is not an existing technology … Creativity means that, 
compared with the existing technologies, the invention possesses prominent substantive features and 
indicates remarkable advancements … .”16 (Italic emphasis added.) 
 
Many other countries in Asia, however, do not explicitly require such improvement or enhancement 
in their patent laws, but rather, leave the national IP authorities to make an assessment based on the 
minimum requirements for patentability required under the TRIPS Agreement (that the invention be 
new, involve an inventive step and is capable of industrial application17). This has led to divergent 
practices.18 
 
In Singapore, such inventions are patentable without any express legislative requirement of an 
improvement/enhancement in therapeutic efficacy. This can be seen from section 14(7) of the 
Patents Act and from Intellectual Property of Singapore (IPOS) practice.19 Under Thai law and 
14  The Indian Supreme Court recently ruled on the relevant provision (section 3(d) of the Indian Patents Act) in a 
landmark case, Novartis AG v Union of India & Others; judgment, 1 April 2013, available at: 
supremecourtofindia.nic.in/outtoday/patent.pdf (accessed 13 June 2014); see esp. paras. 182-195.The Act, as 
amended up to 2013, is available at: ipindia.nic.in/ipr/patent/patent_Act_1970_28012013_book.pdf (accessed 
17 June 2014). 
15  See sections 22.1 and 26.2 of the Universally Accessible Cheaper and Quality Medicines Act 2008 (Republic 
Act No. 9502), and the Implementing Rules. 
16  Art. 22 of the Patent Law of the PRC, amended by Decision of Standing Committee of the National People’s 
Congress 2008; text in English available at website of the State Intellectual Property Office of the People’s 
Republic of China, at: http://english.sipo.gov.cn/laws/lawsregulations/201101/t20110119_566244.html 
(accessed 17 June 2014). 
17  Requirements under Article 27(1), TRIPS. 
18  One example is the acceptability of “Swiss-type” claims in patent applications involving known products: these 
appear to be acceptable in Singapore but not, for instance, in Thailand. For an explanation of a “Swiss-type” 
claim, see the explanation by the European Patent Office (EPO) at: http://www.epo.org/law-practice/legal-
texts/html/guidelines/e/g_vi_7_1.htm (accessed 13 June 2014) – such claims are no longer accepted by the 
EPO. 
19 See IPOS’ Examination Guidelines for Patent Applications at IPOS, 14 February 2014, pp. 234-5. 
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 practice it appears that second medical use claims are no longer patentable. 20  Lao PDR and 
Vietnamese law do not provide for patenting of second medical uses of known products.21 
 
Such divergences have implications for countries aiming at greater integration such as those in 
ASEAN. This is because they affect pricing of pharmaceuticals in ASEAN member countries. They 
also has implications when ASEAN is negotiating an FTA with an external partner which demands, 
for example, increased patentability scope to include second medical uses of known medicines, 
contrary to some of these existing laws, as there appears to be no common negotiating position in 
such matters. Finally, from a foreign investor’s point of view, the divergent regulatory requirements 
can complicate matters for innovators seeking patent protection within the region for their 
pharmaceutical products.22 Such transaction costs can add to costs of the end products, which in 
turn affects availability to the public. 
 
b) Flexibility Accommodating Bolar Exceptions 
 
WTO case law has confirmed that members may, under the TRIPS Agreement, make use of the 
exception in Article 30 - in particular to permit activities for research and preparation for obtaining 
pharmaceutical marketing approval.23 This case law yielded what has come to be known as the Bolar 
exception.24 States in Asia have therefore included research and Bolar exceptions in their patent laws. 
Examples of such countries are Brunei Darussalam,25 China,26 India,27 Malaysia,28 Singapore29 and 
Thailand.30 Hong Kong31 and Lao PDR laws, on the other hand, do not include a Bolar exception 
20  The practice changed in 2011; see report, http://www.asiaiplaw.com/article/41/527/ (accessed 14 June 2014). 
21  For Lao PDR, see Art. 13, Law No. 01/NA, Law on Intellectual Property (as amended, 2011), text available at: 
http://www.wipo.int/wipolex/en/details.jsp?id=13482. For Vietnam, see Arts. 4.12, 58, 59 and 60 of Law No. 
50/2005/QH11 of November 29, 2005 (as amended in 2009), on Intellectual Property, text available at: 
http://www.wipo.int/wipolex/en/details.jsp?id=12011 (accessed 1 May 2014). 
22  While many countries in Asia are parties to the Patent Cooperation Treaty (PCT), done at Washington on 19 
June 1970, amended on 28 September 1979, 
modified on 3 February  1984, and on 3 October 2001 (text available at: 
http://www.wipo.int/pct/en/texts/articles/atoc.htm), which facilitates and simplifies patent filing across 
countries, there are some that are not, such as Cambodia and Myanmar: see 
http://www.wipo.int/pct/en/pct_contracting_states.html (accessed 17 June 2014). (Cambodia is however a 
party to the Paris Convention for the Protection of Industrial Property.) 
23  Canada – Protection of Pharmaceuticals Products, WT/DS114/R, Panel Report, adopted 7 April 2000. 
24  The exception derives its name from a US court decision in Roche Products Inc v Bolar Pharmaceutical Co, 733 F. 2d 
858 (Fed. Circ. 04/23/1984). See also Daniel Gervais, The TRIPS Agreement: Drafting History and Analysis, 3rd 
Edition, Sweet & Maxwell, at pages 381-2. 
25  Patents Order 2011, section 64(2)(b) (experimental purposes) and (2)(g) (for meeting marketing approval 
requirements). 
26  Art. 69(5), Patent Law of the People’s Republic of China; text in English available at China’s SIPO website: 
http://english.sipo.gov.cn/laws/lawsregulations/201101/t20110119_566244.html (accessed 16 June 2014). 
27  Section 107A, Patents Act, 1970. 
28  Section 37(1A), Patents Act. 
29  Section 66(2)(g), Patents Act. 
30  Section 36(4), Patents Act. 
31  See Section 75 Patents Ordinance (http://www.asialaw.com/Article/1972094/Search/Results/Hong-Kong-
Pharmaceutical-Patents-Breaking-the-Ranks.html?Keywords=Bolar+provision). 
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 provision. Indonesian law provides for a research exception but not a Bolar exception.32 Again, for 
ASEAN, the divergences may present a challenge should the matter arise in negotiations with an 
external partner regarding this type of exception. 
 
c) Use of Compulsory Licensing 
The use of compulsory licensing in Asia has also been a point of divergence. Countries such as India, 
Indonesia, Malaysia and Thailand33 have utilized compulsory licensing in recent years. Notably, in 
Thailand, the pharmaceuticals subject to the compulsory licenses have included those for treating 
non-communicable diseases. Countries such as Singapore, on the other hand, have not, and 
Singapore has taken the further step to indicate that it would use compulsory licensing only in 
emergencies or extremely urgent situations. 34  China has legislated to provide for compulsory 
licensing although it has not issued any compulsory license yet. In 2003 and 2005, China issued 
measures on compulsory licenses to address public health problems.35 In 2012, a revised set of 
measures was issued, which repeals these earlier measures.36 Under the 2012 measures, Article 5 to 8 
set the situations in which a compulsory license may be applied for/issued. Article 5 provides for 
situations of a patent holder’s failure to work his patent and where a patent holder is shown to have 
“monopolistic actions”. Article 6 permits grant of compulsory licenses in the following situations: 
“emergency or irregular event of the state, or for the purposes of public interest”. Article 7 permits 
grant of compulsory licenses for manufacture and export of patented medicines in certain situations 
(reflecting the “paragraph 6” waiver mentioned earlier). 
d) Limitation of Patent Opposition Opportunities 
Some national patent systems provide for an opportunity to oppose a patent application. The TRIPS 
Agreement is silent about such proceedings. In some FTAs, however, parties have agreed to 
32  Art. 16(3). 
33  See generally, Ralf Boscheck, Intellectual Property Rights & Compulsory Licensing: The Case of Pharmaceuticals in 
Emerging Markets (2012) W Comp L & Econ Rev, Volume 35 Issue 4) pp. 621 – 634; Sakda Thanitcul and 
Matthew Lim Braslow, Compulsory Licensing of Chronic Disease Pharmaceuticals in Thailand, Thai J. Pharm. Sci. 37 
(2013) 61-83 and Raadhika Gupta, Compulsory Licensing under TRIPS: How Far it Addresses Public Health Concerns in 
Developing Nations (2010) JIPR Vol 15, pp 357-363 . 
34  See http://www.wto.org/english/news_e/pres03_e/pr350_e.htm (accessed 12 June 2014). In addition to 
Singapore, other countries taking this stance are Hong Kong China, Israel, Korea, Kuwait, Macao China, 
Mexico, Qatar, Chinese Taipei, Turkey and United Arab Emirates. For information on various countries’ laws 
implementing the “paragraph 6” system, see http://www.wto.org/english/tratop_e/trips_e/par6laws_e.htm 
(accessed 12 June 2014). 
35  Measures of January 1, 2006, for Compulsory License on Patent Implementation Concerning Public Health Problems 
(promulgated by Order No. 37 of the State Intellectual Property Office (SIPO); see WIPO website at: 
http://www.wipo.int/wipolex/en/details.jsp?id=6518 and 
http://www.wipo.int/wipolex/en/text.jsp?file_id=199481 (accessed 16 June 2014). 
36  Measures for Implementing Compulsory Licensing (No. 31) promulgated by the State Intellectual Property Office on June 13, 
2003, and Measures of March 15, 2012, for Compulsory Licensing of Patent Implementation promulgated by Order No. 64 of 
the State Intellectual Property Office on November 29, 2005(SIPO). 
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 eliminate patent opposition proceedings prior to grant of a patent.  In the US-Singapore FTA, for 
example, Art. 16.7 explicitly removes the right to hold any pre-grant opposition proceedings: 
“Each Party shall provide that a patent may only be revoked on grounds that would have 
justified a refusal to grant the patent, or that pertain to the insufficiency of or unauthorized 
amendments to the patent specification, non-disclosure or misrepresentation of prescribed, 
material particulars, fraud, and misrepresentation. Where such proceedings include opposition 
proceedings, a Party may not make such proceedings available prior to the grant of the patent.” 
 
Any challenge has to be brought post-grant under, for example, provisions on revocation of a 
granted patent. Under US and EU law, post-grant proceedings are available; the US law provides a 
“pre-issuance protest” process while a patent application is still pending. Far from being removed or 
reduced in importance recently, this pre-grant process was in fact expanded by statute in 2012.37 
 
Pre-grant opposition proceedings still exist in some Asian jurisdictions. These include India, 
Indonesia and Thailand.38 Vietnam law permits third parties to “express opinions” on a pending 
application.39 
 
5. Divergence in Participation in Health-Related Treaties and State Relationships with 
Commercial Entities in Related Industries 
Not all Asian states are party to certain multilateral, health-related treaties. For example, signatories 
to the Framework Convention on Tobacco Control established under the auspices of the WHO,40 
37  The Leahy-Smith US America Invents Act: see http://usptopost-grant.com/2011/11/05/new-u-s-opposition-
proceedings-provide-strategic-avenues-for-patent-challengers/ and 
http://www.uspto.gov/aia_implementation/faqs-preissuance-submissions.jsp. The implementing rules setting 
out an amended ‘protest’ process in 37 CFR § 1.291 were published in the Federal Register, Vol. 77, No. 3, 5 
January 2012 (see generally http://www.pharmapatentsblog.com/2012/01/26/proposed-aia-implementation-
rules-preissuance-submissions-in-pending-applications/). The US FTC has defended pre-grant proceedings 
under US law: see FTC, To Improve Innovation: The Proper Balance of Competition and Patent Law and Policy, October 
2003, at p. 18. For the EU, see: http://www.epo.org/applying/european/oppositions.html (accessed 8 March 
2014). Under the UK Patents Act 1977 (as amended) a third party may make “observations” after publication 
of an application, before the grant of a patent.37 While this step may not amount to an opposition proceeding it 
provides third parties with a useful opportunity to provide the Registrar with pertinent information which the 
comptroller “shall consider … in accordance with the rules”. 
38  Section 25 of the Indian Patents Act 1970 (as amended) permits this. For commentaries on this process in 
India, see also Jakkrit Kuanpoth, Patent Rights in Pharmaceuticals in Developing Countries, (2010) Edward Elgar, at pp. 
78-9, and Shivnath Tripathi, Relevance of Pre-Grant Opposition under Indian Law, 9 December 2013, at 
http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2365463 (accessed 8 March 2014). Under Art. 45 of the 
Indonesian Law on Patents, Law Number 14 of 2001, a person may file comments and/or objections prior 
to a grant, after announcement of an application. As to pre-grant opposition proceedings under the Thai 
Patent Patent Act B.E. 2522 (1979), as amended by the Patent Act (No. 2) B.E 2535 (1992) and the Patent Act 
(No. 3) B.E. 2542 (1999), see sections 31, 32 and 34. On patent opposition systems in general, see Opposition 
Systems, World Intellectual Property (WIPO) Standing Committee on the Law of Patents, document prepared 
by the WIPO Secretariat, SCP/14/5, 11 December 2009; available at: 
http://www.wipo.int/meetings/en/doc_details.jsp?doc_id=130408 (accessed 8 March 2014). 
39  Art. 112, Law on Intellectual Property, No. 50/2005/QH11. 
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 include China, Korea, Japan and all members of ASEAN except for Indonesia. While China is a 
signatory, the FCTC has only been extended in a very limited way to Hong Kong.41 
The fact that Indonesia is not a signatory leaves the most populous nation in ASEAN outside the 
health-protection obligations of the FCTC, while the rest of ASEAN is bound by them. This has 
implications as ASEAN negotiates trade and investment agreements with its external partners as a 
bloc (such as the ongoing Regional Comprehensive Economic Partnership Agreement (RCEP) 
negotiations between ASEAN and six of its major trade partners: Australia, China, India, Korea, 
Japan and New Zealand), or as ASEAN members which are FCTC parties negotiate with non-
FCTC parties such as the US (in the TPP negotiations).42 
Divergences in policies may also occur where they are shaped by factors such as whether there 
might be a state entity which is itself involved in tobacco production, distribution or sale, such as in 
Thailand and China), and in the area of pharmaceuticals, the kind of pharmaceutical production or 
R&D activities occurring in their economies. 
 
6. Trade Negotiations and Addressing Public Health Regulation Concerns43 
 
Cost-benefit analysis and trade-offs 
Public authorities need to strike a balance between trade, non-trade benefits, and any disbenefits of 
entering a FTA, especially where the counter-Party’s negotiating demands include a significant 
change to the existing system. An example would be public health regulations such as those affecting 
how medicines are approved, marketed and sold, and who may do so. Another would be balancing 
trade liberalization by removal of tariff and non-tariff barriers with respect to tobacco products 
against existing tobacco control laws, policies and international obligations. The demands of 
negotiation may require considering changes that bring a risk of higher pharmaceutical prices. Finally, 
the potential application of investor-State dispute settlement (such as arbitration) to such provisions 
raise the potential of costly and high-profile disputes brought by investors. 
Authorities through internal consultation often make a final decision which consists of a mix of 
economic and political judgment. As a result, one question that Asian treaty negotiators often have 
to consider is how the product of the final decision will affect the country in the long term, 
especially where a treaty carries investor-State dispute possibilities. In coming to a decision on final 
trade-offs, a negotiator may have to deal with the tension of the potential trade-investment/public 
health interface, such as where TRIPS-plus provisions - not hitherto part of the national system - are 
40  See list of FCTC signatories at: http://www.who.int/fctc/signatories_parties/en/. 
41  Through Article 153 of the Basic Law of the Hong Kong Special Administrative Region of the People's 
Republic of China; see ibid., footnote 1 to China’s entry in the list. 
42  The US has signed but not ratified the FCTC: see http://www.who.int/fctc/signatories_parties/en/ (accessed 
16 June 2014). 
43  On the sources of tension in regulating health and trade, see, for example, some such sources identified 
specifically in the pharmaceutical context in Chapter 10, Abbott & Dukes, Global Pharmaceutical Policy, (2009) 
Edward Elgar. 
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 being demanded. An Asian state may therefore aim to agree to necessary trade-offs but find it 
necessary to ask for safe harbor provisions, to strengthen the quid pro quo. An example that could 
help deal with the tension could be the inclusion of a clear provision for regulatory discretion for 
health (e.g. through GATT-type exceptions) or a request for specific carve-outs for certain measures 
from dispute settlement, to reduce the risk of legal exposure. In this connection, the US-Colombia 
FTA provides interesting language: 
“Article 16.13: Understandings Regarding Certain Public Health Measures  
1. The Parties affirm their commitment to the Declaration on the TRIPS Agreement and 
Public Health (WT/MIN(01)/DEC/2).  
2. The Parties have reached the following understandings regarding this Chapter.  
(a)  The obligations of this Chapter do not and should not prevent a Party from taking 
measures to protect public health by promoting access to medicines for all, in 
particular concerning cases such as HIV/AIDS, tuberculosis, malaria, and other 
epidemics as well as circumstances of extreme urgency or national emergency. 
Accordingly, while reiterating their commitment to this Chapter, the Parties affirm that this Chapter 
can and should be interpreted and implemented in a manner supportive of each Party’s right to 
protect public health and, in particular, to promote access to medicines for all.  
(b)  In recognition of the commitment to access to medicines that are supplied in 
accordance with the Decision of the General Council of 30 August 2003 on the 
Implementation of Paragraph Six of the Doha Declaration on the TRIPS Agreement 
and Public Health (WT/L/540) and the WTO General Council Chairman’s 
statement accompanying the Decision (JOB(03)/177, WT/GC/M/82) (collectively, 
the “TRIPS/health solution”), this Chapter does not and should not prevent the 
effective utilization of the TRIPS/health solution. …” (Italic emphasis added.) 
 
While this provision has not been tested before a tribunal, it provides an express interpretative 
directive with regard to public health goals and the goal of promoting access to medicines “for all”. 
 
7. ASEAN Integration: An Opportunity for Convergence in Health Goals and Regulations 
 
For the diverse members of ASEAN, the ASEAN Economic Community (AEC) is the process of 
formation and is expected to come about by the end of 2015, there is a comprehensive 
implementation plan.44 At the same time ASEAN is seeking further economic integration with six of 
its key regional trade partners, in the negotiations for a RCEP.45 
 
In the area of intellectual property policy, while ASEAN has developed an IP Action Plan46 there is 
no explicit linkage between IP development and treatment of pharmaceutical patents and 
44  See note 9 above. 
45  See text accompanying note 42 above. 
46  ASEAN Intellectual Property Rights Action Plan 2011-2015, available at: ASEAN IP Portal at: 
http://www.aseanip.org/ipportal/index.php?option=com_content&view=article&id=141:asean-ipr-action-
12 
 
                                                          
 compulsory licensing by members. Directions for initiatives on affordable healthcare are also not 
expressly linked to IP policy. There has been no publicly-articulated common FTA negotiating 
stance on provisions which may affect tobacco control. ASEAN leaders did however recently 
expressly resolve to ensure access to affordable healthcare, and affordable medicines (see below).47 
 
The objective of providing affordable healthcare, and affordable medicines in particular, has become 
an increasing explicit one in recent ASEAN integration instruments, such as Ministerial declarations 
and integration agenda. While the AEC plans address economic integration, healthcare and related 
goals and initiatives fall under the purview of the ASEAN Socio-Cultural Community (ASCC) and 
the ASCC sets out the specific actions and initiatives to be carried out for such goals.48 Specifically, 
the ASCC states as one of its “Strategic Objectives”: “Ensure access to adequate and affordable healthcare, 
medical services and medicine, and promote healthy lifestyles for the peoples of ASEAN” (Italic emphasis 
added).49 
In a recent Ministerial Declarations, the following important language was expressed by ASEAN 
heads of State: 
Consistent with the purposes and principles of ASEAN basic instruments to promote health, 
science and technology, education, human resources, cultural heritage, and the high quality of 
life, ASEAN resolves at the global level to: 
a. Ensure access to adequate and affordable healthcare, medical services, as well as accessibility to safe, 
non-counterfeit, affordable, and effective medication …50 (Italic emphasis added.) 
 
There is scope for tension in at least two areas, in implementing the above objectives. First, the 
relative appetite of ASEAN governments for increasing TRIPS-plus protection (such as for 
pharmaceutical patents and related rights such as data protection) in their national systems differs. 
Secondly, ASEAN members desire increased foreign investment and trade but will need to manage 
the affordability of medicines along with changes that economic integration and increasing FTA 
activity may bring. Related to this, ASEAN members (other than Indonesia) will also need to ensure 
a balance between trade and investment obligations and their health-protection obligations such as 
those under FCTC. However, the strong integration objective in ASEAN could also provide an 
opportunity for greater convergence in how to deal with health-related negotiating demands. 
 
8. Conclusion: Seeking A Convergence of Purposes 
plan-2011-2015&catid=218&Itemid=653 (accessed 12 June 2014). The Action Plan does aim to develop a 
“strong negotiating position” via a “minimum” negotiating framework for IPRs, though (para. 25). 
47  Para. C.3(a), Bali Concord III, note 9 above. 
48  See paras B4-B5, Roadmap for an ASEAN Community 2009-2015; text available at ASEAN website at: 
http://www.asean.org/resources/publications/asean-publications/item/roadmap-for-an-asean-community-
2009-2015 (accessed 13 June 2014).  
49  Para. B4, ibid. 
50  Para C.3(a), Bali Concord III, note 9 above. 
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 Given divergences such as those mentioned in this article, one may question if convergence within 
Asia on trade, investment and health laws is relevant or feasible. For those seeking closer integration 
and harmonization, it is – but to a point. For this to materialize, there must first be a convergence of 
purposes with regard to trade and health, especially among those seeking closer economic and other 
regional integration. The following are some possible, practical steps toward such convergence. First, 
it is necessary to identify common interests and priority health goals across borders. Given that there 
are diverse economic and public health needs within Asia, such a first step will create a common 
platform for better collaborative and coordinated regulatory responses. Secondly, it is imperative to 
identify and express common, necessary regulatory space for public health measures in trade and 
investment treaty negotiations. Thirdly, a helpful step would be discussion and design for inclusion 
in trade/investment treaties of non-contentious, problem-solving dispute settlement methods with 
regard to health-related regulation disputes, so that lasting, innovative solutions that are oriented 
toward meeting trade and health goals can be forged. It is submitted that such steps can help policy-
makers bring about greater convergence, so as to better handle tensions arising from the trade-
investment-public health interface as it arises in domestic rule-making and in treaty-making. 
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